GammaCan International to Present IgG-Based Melanoma Program at the 5th Annual BioPartnering North America
February 01 2007 - 6:30AM
Business Wire
GammaCan International, Inc. (OTC BB: GCAN), a developer of
immunotherapies for the treatment of cancer, today announced that
Patrick Schnegelsberg, Chief Executive Officer, is scheduled to
present VitiGam, GammaCan's lead product under development for the
treatment of stage III and IV melanoma, to the investor,
biotechnology and pharma communities at the BioPartnering North
America Conference. The conference will be held at the Westin
Bayshore Resort and Marina in Vancouver, B.C., Canada, during
February 4-6, 2007. Mr. Schnegelsberg is scheduled to present on
Monday, February 5th at 11:30 PST. About VitiGam: VitiGam is
GammaCan's second generation intravenous IgG-based product and a
first-in-class anti-cancer immunotherapy. GammaCan plans on having
VitiGam to enter phase I/II testing under a US IND in the near
future after it recently held a pre-IND meeting with the FDA.
VitiGam is being designed to target metastatic melanoma patients
with Stage III and IV melanoma. VitiGam is an IgG product that is
different from standard IgGs: It is manufactured from the plasma of
donors with vitiligo, a benign autoimmune skin condition affecting
up to 2% of the general population. GammaCan scientists have shown
that this "enriched" vitiligo IgG (VitiGam) contains potent
anti-melanoma activity in both in vitro and mouse xenograft
melanoma models. Thus, GammaCan expects VitiGam to provide (1)
anti-melanoma activity directed specifically against malignant
melanoma cells and (2) non-specific anti-cancer activity - as is
the case with IgG in general. About GammaCan GammaCan is focusing
on the commercialization of an innovative anti-cancer immunotherapy
to treat metastatic cancer. GammaCan's platform is based on IgG, a
safe, relatively non-toxic human plasma-based product, currently
used to treat a variety of immune deficiencies and autoimmune
diseases. IgG works by strengthening the patient's immune system.
Many experts currently view immunotherapy as a future alternative
to today's standard chemotherapy. GammaCan is developing VitiGam,
its second generation program. VitiGam is an IgG derived from the
plasma of vitiligo donors and is being developed to treat malignant
melanoma. GammaCan owns, and has applied for US patent protection
covering the use of IgG and vitiligo-derived IgG (VitiGam). For
more information about GammaCan visit www.GammaCan.com or call the
company's headquarters in Kiryat Ono, Israel at +972 (03) 738-2616
or toll free 1-866-308-0396 (from North America). Safe Harbor
Statement: Statements in this document that are not purely
historical are forward-looking statements. Forward-looking
statements in this release include statements regarding: the
commercialization of an anti-cancer immunotherapy and the Company
developing the boosting of cancer patients' immune systems with
IVIG into an effective treatment. Actual outcomes and the Company's
actual results could differ materially from those in such
forward-looking statements. Factors that could cause actual results
to differ materially include risks and uncertainties such as the
inability to finance the planned development of the technology,
inability to hire appropriate staff to develop the technology,
unforeseen technical difficulties in developing the technology,
inability to obtain regulatory approval for human use, competitors'
therapies proving more effective, cheaper or otherwise preferable
for consumers, inability to market the product we produce, among
other factors, all of which could among other things, delay or
prevent product release or cause our company to fail. For further
risk factors see the risk factors associated with other early stage
medical research and development companies filed with the SEC on
Edgar.
Greater Cannabis (PK) (USOTC:GCAN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Greater Cannabis (PK) (USOTC:GCAN)
Historical Stock Chart
From Jul 2023 to Jul 2024